株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の核医学市場:2025年までの予測と市場機会

Global Nuclear Medicine Market By Therapy, By Type, By Application, By Therapeutics, By Route of Administration, By End-User, By Region, Forecast & Opportunities, 2025

発行 TechSci Research 商品コード 934739
出版日 ページ情報 英文 110 Pages
納期: お問合せ
価格
本日の銀行送金レート: 1USD=110.09円で換算しております。

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

世界の核医学市場:2025年までの予測と市場機会 Global Nuclear Medicine Market By Therapy, By Type, By Application, By Therapeutics, By Route of Administration, By End-User, By Region, Forecast & Opportunities, 2025
出版日: 2020年05月01日 ページ情報: 英文 110 Pages
概要

世界の核医学市場は、癌などの疾患の発生率と有病率の増加、Mo-99の需要と供給のギャップを削減する取り組み、また、さまざまな治療のための放射線療法の研究開発活動の増加により、2025年まで目覚ましい速度で成長すると予測されています。さらに、核医学は分子イメージングで広く使用されています。分子イメージングは、疾患の発症または進行を決定する特定の分子プロセスのバイオマーカーとして分子を使用する手法です。

当レポートは、世界の核医学市場を、治療別、タイプ別、用途別、治療学別、投与経路別、エンドユーザー別、地域別で調査したもので、市場規模や市場シェアの予測、促進要因と課題、競合情勢、主要企業プロファイルなどの情報を提供しています。

目次

第1章 製品の概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の核医学市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 治療別(放射性ヨウ素、放射性抗体、放射性リン、その他)
    • タイプ別(SPECT(シングルフォトエミッションコンピューター断層撮影)、PET(陽電子放出断層撮影)、アルファエミッター、ベータエミッター、近接照射療法)
    • 用途別(循環器、呼吸器、整形外科、神経学、腫瘍学、泌尿器科)
    • 治療学別(アルファ粒子エミッター、ベータ粒子エミッター、オージェ電子エミッター)
    • 投与経路別(経口、点滴、経鼻)
    • エンドユーザー別(病院、診断センター、その他)
    • 企業別(2019年)
    • 地域別
  • 市場魅力指数

第6章 アジア太平洋の核医学市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 治療別
    • タイプ別
    • 用途別
    • 治療学別
    • 投与経路別
    • エンドユーザー別
    • 国別
  • 市場魅力指数
  • アジア太平洋地域:国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • シンガポール
    • オーストラリア

第7章 欧州の核医学市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 治療別
    • タイプ別
    • 用途別
    • 治療学別
    • 投与経路別
    • エンドユーザー別
    • 国別
  • 市場魅力指数
  • 欧州:国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • ロシア
    • スペイン

第8章 北米の核医学市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 治療別
    • タイプ別
    • 用途別
    • 治療学別
    • 投与経路別
    • エンドユーザー別
    • 国別
  • 市場魅力指数
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第9章 南米の核医学市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 治療別
    • タイプ別
    • 用途別
    • 治療学別
    • 投与経路別
    • エンドユーザー別
    • 国別
  • 市場魅力指数
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの核医学市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 治療別
    • タイプ別
    • 用途別
    • 治療学別
    • 投与経路別
    • エンドユーザー別
    • 国別
  • 市場魅力指数
  • 中東・アフリカ地域:国別分析
    • 南アフリカ
    • サウジアラビア
    • UAE

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

第13章 競合情勢

  • 競合の展望
  • 主要企業プロファイル
    • Cardinal Health
    • Curium
    • Lantheus
    • Bracco
    • Advanced Accelerator Applications
    • NTP Radioisotopes
    • Eckert & Ziegler
    • Jubilant DraxImage
    • GE Healthcare
    • Siemens Healthineers
    • Rotem Industries
    • Eczacibasi-Monrol
    • IBA Group
    • Ire-Elit
    • Lucerno Dynamics
    • Positron Corporation
    • NorthStar Medical Radioisotopes
    • Pharmalucence
    • Norgine
    • Roche

第14章 戦略的推奨事項

第15章 会社と免責事項について

目次
Product Code: 4562

Global nuclear medicine market is estimated to grow at an impressive rate during the forecast period owing to increasing incidence and prevalence of diseases like cancer, initiatives to reduce the demand and supply gap of Mo-99 and increasing research and development activities in radiotherapy to treat various diseases. Furthermore, nuclear medicines are extensively being used in molecular imaging, which is a technique involving molecules as biomarkers for specific molecular processes that determines the onset or progress of a disease.

Nuclear medicines are convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Due to this major factor, chemotherapy methods are being replaced by radiopharmaceuticals or nuclear medicines for cancer treatment. They are also used in applications such as lymphoma and bone metastasis. Some of the nuclear medicines used in diagnostic procedures are F-18, Tc-99, Ga-67, and I-123 while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures. These factors are anticipated to drive global nuclear medicine market until 2025.

Apart from above mentioned growth factors, the global nuclear medicine market also faces some restrains. Short half-life of nuclear medicines or radiopharmaceuticals reduces their potential adoption. Other restraining factors include supply shortages, logistical difficulties, and limited number of trained medical personnel.

The global nuclear medicine market is segmented based on therapy, type, application, therapeutics, route of administration, end-user and region. Based on application, the global nuclear medicine market is segmented into cardiology, respiratory, orthopaedics, neurology, oncology and urology. Among them, the oncology segment accounts for the major market share due to increasing prevalence of cancer worldwide. Based on type, the nuclear medicine market is segmented into SPECT, PET, alpha-emitters, beta-emitters and brachytherapy. The SPECT segment accounts for the largest market share and is expected to hold its dominance in the coming years owing to low cost and wide usage in different applications.

Major players operating in the global nuclear medicine market include Cardinal Health, Curium, Lantheus, Bracco, Advanced Accelerator Applications, NTP Radioisotopes, Eckert & Ziegler, Jubilant DraxImage, GE Healthcare, Siemens Healthineers, Rotem Industries, Eczacibasi-Monrol, IBA Group, Ire-Elit, Lucerno Dynamics, Positron Corporation, NorthStar Medical Radioisotopes, Pharmalucence, Norgine, Roche and others. Key market players are implementing activities like product developments, business expansion, and collaborative development to maintain significant share in the market for nuclear medicine.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study

  • To analyze and forecast the market size of global nuclear medicine market.
  • To classify and forecast global nuclear medicine market based on therapy, type, application, therapeutics, route of administration, end-user, company and regional distribution.
  • To identify drivers and challenges for global nuclear medicine market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global nuclear medicine market.
  • To conduct pricing analysis for global nuclear medicine market.
  • To identify and analyze the profile of leading players operating in global nuclear medicine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global nuclear medicine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience

  • Nuclear medicine manufacturer, suppliers, distributors and other stakeholders
  • Hospitals & Clinics
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to nuclear medicine
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global nuclear medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Therapy:

Radioactive Iodine

Radioactive Antibodies

Radioactive Phosphorus

Others

  • Market, By Type:

SPECT (Single Photo Emission Computed Tomography)

PET (Positron Emission Tomography)

Alpha-emitters

Beta-emitters

Brachytherapy

  • Market, By Application:

Cardiology

Respiratory

Orthopaedics

Neurology

Oncology

Urology

  • Market, By Therapeutics:

Alpha Particle Emitters

Beta Particle Emitters

Auger Electron Emitters

  • Market, By Route of Administration:

Oral

Intravenous

Nasal

  • Market, By End-User:

Hospitals

Diagnostic Centers

Others

  • Market, By Region:

Asia-Pacific

Europe

North America

South America

Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global nuclear medicine market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Nuclear Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy (Radioactive Iodine, Radioactive Antibodies, Radioactive Phosphorus, Others
    • 5.2.2. By Type (SPECT (Single photo emission computed tomography), PET (Positron emission tomography), Alpha-emitters, Beta-emitters, Brachytherapy)
    • 5.2.3. By Application (Cardiology, Respiratory, Orthopaedics, Neurology, Oncology, Urology)
    • 5.2.4. By Therapeutics (Alpha Particle Emitters, Beta Particle Emitters, Auger Electron Emitters)
    • 5.2.5. By Route of Administration (Oral, Intravenous, Nasal)
    • 5.2.6. By End-User (Hospitals, Diagnostic centers, Others)
    • 5.2.7. By Company (2019)
    • 5.2.8. By Region
  • 5.3. Market Attractiveness Index

6. Asia-Pacific Nuclear Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Type
    • 6.2.3. By Application
    • 6.2.4. By Therapeutics
    • 6.2.5. By Route of Administration
    • 6.2.6. By End-User
    • 6.2.7. By Country
  • 6.3. Market Attractiveness Index
  • 6.4. Asia-Pacific: Country Analysis
    • 6.4.1. China Nuclear Medicine Market Outlook
      • 6.4.1.1. Market Size & Forecast
        • 6.4.1.1.1. By Value
      • 6.4.1.2. Market Share & Forecast
        • 6.4.1.2.1. By Therapy
        • 6.4.1.2.2. By Type
        • 6.4.1.2.3. By Application
        • 6.4.1.2.4. By Therapeutics
        • 6.4.1.2.5. By Route of Administration
        • 6.4.1.2.6. By End-User
    • 6.4.2. India Nuclear Medicine Market Outlook
      • 6.4.2.1. Market Size & Forecast
        • 6.4.2.1.1. By Value
      • 6.4.2.2. Market Share & Forecast
        • 6.4.2.2.1. By Therapy
        • 6.4.2.2.2. By Type
        • 6.4.2.2.3. By Application
        • 6.4.2.2.4. By Therapeutics
        • 6.4.2.2.5. By Route of Administration
        • 6.4.2.2.6. By End-User
    • 6.4.3. Japan Nuclear Medicine Market Outlook
      • 6.4.3.1. Market Size & Forecast
        • 6.4.3.1.1. By Value
      • 6.4.3.2. Market Share & Forecast
        • 6.4.3.2.1. By Therapy
        • 6.4.3.2.2. By Type
        • 6.4.3.2.3. By Application
        • 6.4.3.2.4. By Therapeutics
        • 6.4.3.2.5. By Route of Administration
        • 6.4.3.2.6. By End-User
    • 6.4.4. South Korea Nuclear Medicine Market Outlook
      • 6.4.4.1. Market Size & Forecast
        • 6.4.4.1.1. By Value
      • 6.4.4.2. Market Share & Forecast
        • 6.4.4.2.1. By Therapy
        • 6.4.4.2.2. By Type
        • 6.4.4.2.3. By Application
        • 6.4.4.2.4. By Therapeutics
        • 6.4.4.2.5. By Route of Administration
        • 6.4.4.2.6. By End-User
    • 6.4.5. Singapore Nuclear Medicine Market Outlook
      • 6.4.5.1. Market Size & Forecast
        • 6.4.5.1.1. By Value
      • 6.4.5.2. Market Share & Forecast
        • 6.4.5.2.1. By Therapy
        • 6.4.5.2.2. By Type
        • 6.4.5.2.3. By Application
        • 6.4.5.2.4. By Therapeutics
        • 6.4.5.2.5. By Route of Administration
        • 6.4.5.2.6. By End-User
    • 6.4.6. Australia Nuclear Medicine Market Outlook
      • 6.4.6.1. Market Size & Forecast
        • 6.4.6.1.1. By Value
      • 6.4.6.2. Market Share & Forecast
        • 6.4.6.2.1. By Therapy
        • 6.4.6.2.2. By Type
        • 6.4.6.2.3. By Application
        • 6.4.6.2.4. By Therapeutics
        • 6.4.6.2.5. By Route of Administration
        • 6.4.6.2.6. By End-User

7. Europe Nuclear Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Type
    • 7.2.3. By Application
    • 7.2.4. By Therapeutics
    • 7.2.5. By Route of Administration
    • 7.2.6. By End-User
    • 7.2.7. By Country
  • 7.3. Market Attractiveness Index
  • 7.4. Europe: Country Analysis
    • 7.4.1. France Nuclear Medicine Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Therapy
        • 7.4.1.2.2. By Type
        • 7.4.1.2.3. By Application
        • 7.4.1.2.4. By Therapeutics
        • 7.4.1.2.5. By Route of Administration
        • 7.4.1.2.6. By End-User
    • 7.4.2. Germany Nuclear Medicine Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Therapy
        • 7.4.2.2.2. By Type
        • 7.4.2.2.3. By Application
        • 7.4.2.2.4. By Therapeutics
        • 7.4.2.2.5. By Route of Administration
        • 7.4.2.2.6. By End-User
    • 7.4.3. United Kingdom Nuclear Medicine Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Therapy
        • 7.4.3.2.2. By Type
        • 7.4.3.2.3. By Application
        • 7.4.3.2.4. By Therapeutics
        • 7.4.3.2.5. By Route of Administration
        • 7.4.3.2.6. By End-User
    • 7.4.4. Italy Nuclear Medicine Market Outlook
      • 7.4.4.1. Market Size & Forecast
        • 7.4.4.1.1. By Value
      • 7.4.4.2. Market Share & Forecast
        • 7.4.4.2.1. By Therapy
        • 7.4.4.2.2. By Type
        • 7.4.4.2.3. By Application
        • 7.4.4.2.4. By Therapeutics
        • 7.4.4.2.5. By Route of Administration
        • 7.4.4.2.6. By End-User
    • 7.4.5. Russia Nuclear Medicine Market Outlook
      • 7.4.5.1. Market Size & Forecast
        • 7.4.5.1.1. By Value
      • 7.4.5.2. Market Share & Forecast
        • 7.4.5.2.1. By Therapy
        • 7.4.5.2.2. By Type
        • 7.4.5.2.3. By Application
        • 7.4.5.2.4. By Therapeutics
        • 7.4.5.2.5. By Route of Administration
        • 7.4.5.2.6. By End-User
    • 7.4.6. Spain Nuclear Medicine Market Outlook
      • 7.4.6.1. Market Size & Forecast
        • 7.4.6.1.1. By Value
      • 7.4.6.2. Market Share & Forecast
        • 7.4.6.2.1. By Therapy
        • 7.4.6.2.2. By Type
        • 7.4.6.2.3. By Application
        • 7.4.6.2.4. By Therapeutics
        • 7.4.6.2.5. By Route of Administration
        • 7.4.6.2.6. By End-User

8. North America Nuclear Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Type
    • 8.2.3. By Application
    • 8.2.4. By Therapeutics
    • 8.2.5. By Route of Administration
    • 8.2.6. By End-User
    • 8.2.7. By Country
  • 8.3. Market Attractiveness Index
  • 8.4. North America: Country Analysis
    • 8.4.1. United States Nuclear Medicine Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Therapy
        • 8.4.1.2.2. By Type
        • 8.4.1.2.3. By Application
        • 8.4.1.2.4. By Therapeutics
        • 8.4.1.2.5. By Route of Administration
        • 8.4.1.2.6. By End-User
    • 8.4.2. Mexico Nuclear Medicine Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Therapy
        • 8.4.2.2.2. By Type
        • 8.4.2.2.3. By Application
        • 8.4.2.2.4. By Therapeutics
        • 8.4.2.2.5. By Route of Administration
        • 8.4.2.2.6. By End-User
    • 8.4.3. Canada Nuclear Medicine Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Therapy
        • 8.4.3.2.2. By Type
        • 8.4.3.2.3. By Application
        • 8.4.3.2.4. By Therapeutics
        • 8.4.3.2.5. By Route of Administration
        • 8.4.3.2.6. By End-User

9. South America Nuclear Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Type
    • 9.2.3. By Application
    • 9.2.4. By Therapeutics
    • 9.2.5. By Route of Administration
    • 9.2.6. By End-User
    • 9.2.7. By Country
  • 9.3. Market Attractiveness Index
  • 9.4. South America: Country Analysis
    • 9.4.1. Brazil Nuclear Medicine Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Therapy
        • 9.4.1.2.2. By Type
        • 9.4.1.2.3. By Application
        • 9.4.1.2.4. By Therapeutics
        • 9.4.1.2.5. By Route of Administration
        • 9.4.1.2.6. By End-User
    • 9.4.2. Argentina Nuclear Medicine Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Therapy
        • 9.4.2.2.2. By Type
        • 9.4.2.2.3. By Application
        • 9.4.2.2.4. By Therapeutics
        • 9.4.2.2.5. By Route of Administration
        • 9.4.2.2.6. By End-User
    • 9.4.3. Colombia Nuclear Medicine Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Therapy
        • 9.4.3.2.2. By Type
        • 9.4.3.2.3. By Application
        • 9.4.3.2.4. By Therapeutics
        • 9.4.3.2.5. By Route of Administration
        • 9.4.3.2.6. By End-User

10. Middle East and Africa Nuclear Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Type
    • 10.2.3. By Application
    • 10.2.4. By Therapeutics
    • 10.2.5. By Route of Administration
    • 10.2.6. By End-User
    • 10.2.7. By Country
  • 10.3. Market Attractiveness Index
  • 10.4. MEA: Country Analysis
    • 10.4.1. South Africa Nuclear Medicine Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Therapy
        • 10.4.1.2.2. By Type
        • 10.4.1.2.3. By Application
        • 10.4.1.2.4. By Therapeutics
        • 10.4.1.2.5. By Route of Administration
        • 10.4.1.2.6. By End-User
    • 10.4.2. Saudi Arabia Nuclear Medicine Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Therapy
        • 10.4.2.2.2. By Type
        • 10.4.2.2.3. By Application
        • 10.4.2.2.4. By Therapeutics
        • 10.4.2.2.5. By Route of Administration
        • 10.4.2.2.6. By End-User
    • 10.4.3. UAE Nuclear Medicine Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Therapy
        • 10.4.3.2.2. By Type
        • 10.4.3.2.3. By Application
        • 10.4.3.2.4. By Therapeutics
        • 10.4.3.2.5. By Route of Administration
        • 10.4.3.2.6. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Competition Outlook
  • 13.2. Players Profiled (Leading Companies)
    • 13.2.1. Cardinal Health
    • 13.2.2. Curium
    • 13.2.3. Lantheus
    • 13.2.4. Bracco
    • 13.2.5. Advanced Accelerator Applications
    • 13.2.6. NTP Radioisotopes
    • 13.2.7. Eckert & Ziegler
    • 13.2.8. Jubilant DraxImage
    • 13.2.9. GE Healthcare
    • 13.2.10. Siemens Healthineers
    • 13.2.11. Rotem Industries
    • 13.2.12. Eczacibasi-Monrol
    • 13.2.13. IBA Group
    • 13.2.14. Ire-Elit
    • 13.2.15. Lucerno Dynamics
    • 13.2.16. Positron Corporation
    • 13.2.17. NorthStar Medical Radioisotopes
    • 13.2.18. Pharmalucence
    • 13.2.19. Norgine
    • 13.2.20. Roche

14. Strategic Recommendations

15. About Us & Disclaimer